Dark

Check out our Dark Pool Levels

MSLE
Satellos Bioscience Inc. Common Stock
stock NASDAQ

At Close

Jul 22, 2026 3:59:40 PM EDT

9.66USD+13.314%(+1.14)112,172

7.16Bid 22.80Ask 15.64Spread

Pre-market

0.00USD0.000%(0.00)0

After-hours

Jul 22, 2026 4:46:30 PM EDT

9.86USD+2.051%(+0.20)684

Overview HistoricalExchangesShortsTrends

MSLE Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

MSLE Specific Mentions

As of Jul 22, 2026 8:11:18 PM EDT (1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

17 days ago • u/jerrysburner • r/biotech_stocks • dont_miss_msle_satellos_bioscience • C

I asked Gemini:
Yes, Satellos Bioscience (MSLE) has a highly anticipated, major clinical catalyst scheduled for **Wednesday, July 8, 2026**. \[[1](https://investingnews.com/satellos-to-present-clinical-program-updates-at-icnmd-2026/)\]
The company will be featuring new data from its clinical development programs at the **19th International Congress on Neuromuscular Diseases (ICNMD)** in Florence, Italy. Because this is the stock's first major data presentation since uplisting to the Nasdaq, biotech analysts and retail investors are watching this event closely. \[[1](https://www.otcmarkets.com/stock/MSLE/news/Satellos-Reports-First-Quarter-2026-Financial-Results-and-Highlights-Company-Progress?e&id=3468915), [2](https://investingnews.com/satellos-to-present-clinical-program-updates-at-icnmd-2026/), [3](https://maandhunter.substack.com/p/sunday-week-ahead-147), [4](https://www.streetwisereports.com/article/2026/07/01/drug-developer-scores-major-fda-nod-eyes-big-gains-in-muscle-disease-market.html)\]
the references should be good; if it's just a presentation, I don't know that it will have much of an influence on the stock price

17 days ago • u/jerrysburner • r/biotech_stocks • dont_miss_msle_satellos_bioscience • C

I asked Gemini:
Yes, Satellos Bioscience (MSLE) has a highly anticipated, major clinical catalyst scheduled for **Wednesday, July 8, 2026**. \[[1](https://investingnews.com/satellos-to-present-clinical-program-updates-at-icnmd-2026/)\]
The company will be featuring new data from its clinical development programs at the **19th International Congress on Neuromuscular Diseases (ICNMD)** in Florence, Italy. Because this is the stock's first major data presentation since uplisting to the Nasdaq, biotech analysts and retail investors are watching this event closely. \[[1](https://www.otcmarkets.com/stock/MSLE/news/Satellos-Reports-First-Quarter-2026-Financial-Results-and-Highlights-Company-Progress?e&id=3468915), [2](https://investingnews.com/satellos-to-present-clinical-program-updates-at-icnmd-2026/), [3](https://maandhunter.substack.com/p/sunday-week-ahead-147), [4](https://www.streetwisereports.com/article/2026/07/01/drug-developer-scores-major-fda-nod-eyes-big-gains-in-muscle-disease-market.html)\]
the references should be good; if it's just a presentation, I don't know that it will have much of an influence on the stock price

Share